The Period That Came Back

Two opposite searches, one explanation

Type "ozempic made my period" into Google and watch what it offers to finish: stop. Come back. Late. Lighter. Regular.

Those are contradictory outcomes, suggested with roughly equal confidence, which usually means a search engine is reflecting something genuinely mixed rather than one clean effect. And it is: for a great many women the cycle changes on these drugs, and the direction depends almost entirely on where they started.

None of it is on the labels. What follows is the reported version — the pattern, the mechanism, and the part that catches people out.

One boundary first, because it decides whether this is your page. This piece is about whether a period arrives at all. If yours never went anywhere and has simply changed character — heavier, longer, more painful, or a premenstrual week that has become unrecognizable — that is a different mechanism with a different answer, and it is covered separately.

The women whose periods came back

This is the better-evidenced direction, and it is not really about the drug.

Weight and ovulation are linked. A systematic review and network meta-analysis compared exercise, diet and pharmacological interventions in reproductive-aged women with overweight or obesity and looked directly at effects on BMI, ovulation and hormonal profile¹. Weight reduction moves ovulation.

For women with PCOS the picture is sharper still. A systematic review and meta-analysis of liraglutide — a GLP-1 — in women with PCOS assessed metabolic and reproductive outcomes², and a 2026 narrative review examines GLP-1 receptor agonists and fertility restoration in women of reproductive age specifically³. A six-month Italian protocol took 96 women with excess weight and the irregular, anovulatory cycles of polyendocrine metabolic ovarian syndrome; after semaglutide, ovulatory cycles were observed in 52.5% of the previously anovulatory women, with results best in those who were overweight rather than severely obese⁴.

Catera Bentley, then 25 and living in Steele, Alabama, was interviewed by CNN in 2024 about exactly this arc. Her doctor had told her that PCOS might mean she could not conceive. Over her first few months on Mounjaro she lost about 40 pounds and, as CNN put it, her menstrual cycles, "which had been irregular because of PCOS, became normal". "It just made me feel like a whole new person," she said⁵.

Read plainly: if cycles were irregular or absent because of weight and insulin resistance, losing weight can restart them. That is not a side effect. For some women it is the most significant thing the medication did, and nobody warned them it might.

The women whose periods went strange

The other direction is less studied and more likely to be about the manner of the loss rather than the drug. Rapid weight reduction, low energy intake and the physical stress of a body changing fast can all disturb a cycle. This is old physiology, well described outside GLP-1s, and there is no trial isolating it here.

It is not a fringe worry, either. In 2026 a working group convened by the Japan Society for the Study of Obesity proposed an entirely new disease concept — Female Underweight/Undernutrition Syndrome — noting that roughly 20% of Japanese women in their twenties are underweight, and that underweight and undernutrition carry menstrual abnormalities among their consequences. The off-label use of GLP-1 receptor agonists is named in that statement as one of the factors driving the pattern⁶.

Which is why "is this the medication?" is usually the wrong question. The more useful one is "is this what my body does when it loses weight quickly?"

★ The part that catches people out

Here is the thing that turns a biology story into an urgent one.

Returning ovulation means returning fertility, and it can return before a period does — ovulation comes first. Daniel Drucker, the University of Toronto researcher who helped pioneer the science behind this drug class, described the trap to CNN in one sentence: a woman with obesity who does not have frequent periods starts one of these medicines, loses weight over several months and finds she is still not having regular periods — "only now it might be because you're pregnant"⁵.

Women who had spent years assuming they could not easily conceive have found otherwise. The phenomenon has a nickname now — "Ozempic babies" — which is how you know it is common.

And the contraception itself may be affected. The prescribing information for tirzepatide instructs patients using oral hormonal contraceptives to switch to a non-oral method, or add a barrier method, for four weeks after starting and for four weeks after each dose increase⁷. Non-oral hormonal contraception is not affected. Semaglutide's label carries no such instruction.

So on tirzepatide the two things arrive together: fertility potentially returning, and the pill potentially working less well, at exactly the moments the dose is moving. That combination is the single most important paragraph on this page, and it is buried in a document almost nobody reads.

The internet got here first, and got ahead of itself

The talk ran well in front of the evidence, and someone thought to measure the gap. In 2025 a team of reproductive endocrinologists published a study in PLOS ONE setting social media discourse about GLP-1s and fertility against the published literature. They ran sentiment analysis on Reddit and scored Twitter and TikTok posts by hand, with Google Trends alongside. On every platform sentiment came out significantly more positive than neutral, and more neutral than negative. Then they went to PubMed and found 52 original studies in women with polycystic ovary syndrome, all of them positive in sentiment — and, in their words, "a lack of PubMed studies pertaining to the effect of GLP-1 RA in women without PCOS"⁸.

Their conclusion is the shape of this whole story: "The Positive sentiments among women without PCOS is not justified by evidence-based medicine." Where PCOS is in the picture, the optimism is earned. Where it is not, the internet is running on hope and anecdote — and a woman reading it has no way of telling which of the two she is looking at.

The question that would have helped

Not "are you trying to conceive". It is "what are you using, and is it oral?"

There is now published evidence that the conversation is not reliably happening at all. A qualitative study in JAMA Network Open in 2026 ran semi-structured video interviews with 30 adults taking or recently off GLP-1s, 19 of them women, across 15 US states. One of its eight themes was that information provision and clinical support are essential but highly variable: participants described "brief, transactional clinical encounters in which prescriptions were provided with little discussion or opportunity to ask questions", and asked for concrete guidance on what to expect rather than exhaustive lists of rare adverse effects⁹.

Clinicians describe the same gap from the other side of the desk. Manijeh Kamyar, a maternal-fetal medicine specialist and OB-GYN in Las Vegas, told TODAY that patients usually tell her nobody has discussed the risks of Ozempic with them. "I think that that's a huge gap in the use of this medication, especially when something like this ramps up so quickly," she said¹⁰.

So if your cycle changes on a GLP-1, take it back to the clinician who prescribed it rather than filing it under side effects to be endured — because a returning cycle may be good news, a disappearing one deserves a look, and the contraception question has a different answer depending on which molecule you are taking.